Mankind

Serving Life

July 30, 2026

BSE Limited
P J Towers,
Dalal Street,
Mumbai – 400 001

Scrip Code: 543904

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Press Release – Q1 FY27

Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Please find enclosed herewith the Press Release on Financial Results of the Company for the quarter ended on June 30, 2026.

The above-mentioned Press Release is also being uploaded on the website of the company i.e. www.mankindpharma.com.

You are requested to kindly take the above information on your records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

HITESH KUMAR JAIN

Digitally signed by HITESH KUMAR JAIN
Date: 2026.07.30 15:51:53 +05'30'

Hitesh Kumar Jain
Company Secretary &
Compliance Officer

Encl.: A/a

Press Release

Strong Q1FY27 - Revenue growth of 13%; EBITDA growth of 25%; PAT growth of 29%

New Delhi, India, 30th July, 2026: Mankind Pharma (BSE: 543904 | NSE: MANKIND) India's fourth largest pharmaceutical Company today announced its financial results for the first quarter ended 30th June 2026. The information mentioned in this release is based on consolidated financial statements.

	Revenues	Dom. Revenue*	EBITDA
Q1 FY27	INR 4,031 Crore **12.9% YoY** ↑	INR 3,180 Crore **11.0% YoY** ↑	INR 1,060 Crore **24.7% YoY** ↑

Note - Domestic business excluding Consumer Healthcare*

Mr. Rajeev Juneja – Vice Chairman & Managing Director

- ***Revenue grew ~13% YoY with EBITDA margins improving by 250bps to 26.3%***
- ***Overall domestic business (ex CH) grew by 11.0% led by:***
  - ✓ ***Double digit growth in Mankind domestic business with 15.8% growth in Chronic - 19.4% in cardiac and 12.7% in anti-diabetes***
  - ✓ ***Outperformance in Gastro, VMN, Gynaec led to growth recovery in acute***
  - ✓ ***Strong double digit growth in BSV domestic specialty business***
- ***OTC segment grew by ~4%; while International business grew 29%***
- ***Our disciplined execution and strengthening business fundamentals, resulted in improvements across key operating and financial metrics in Q1FY27, laying the foundation to deliver long-term sustainable growth***

Q1 FY27 Performance Summary

- Revenue from Operations at INR 4,031 Cr, up by 12.9% YoY
  - Domestic revenue at INR 3,426 Cr, up 10.5%, Exports at INR 605 Cr, up 29.0% YoY
- EBITDA margin of 26.3%, up by 250 bps YoY and PAT margin of 14.2%, up 170 bps YoY
- Diluted EPS[1] of INR 13.7, up 29.6% YoY (FV Re.1)

1. Diluted EPS not annualised

Press Release

Domestic Business[1]

- Domestic revenue (ex-Consumer Health)[2] increased 11.0% YoY driven by double digit growth in Mankind business, supported by strong growth in BSV specialty business
- Secondary sales growth of 12.7% vs 13.0% IPM[3] in Q1FY27 – primarily due to:
  - strong performance in chronic growth supported by 19.4% in Cardiac and 12.7% in Anti-Diabetes[3]
  - outperformance in Gastro (1.2x), VMN (1.2x), Gynaec (1.05x) led to growth recovery in acute, also recovery seen in anti-invectives (3.6% in Q1FY27 vs -1.1% in Q4FY26)
- Strong growth in key focused brands:
  - outperformance in key acute brands like Cefakind-CV (1.2x), Nurokind-LC (1.1x), Pantakind (1.8x), Dydroboon (1.5x) etc. in Q1FY27
  - 21% growth in Telmikind family; 30%/31% in Lipirose / Statpure in cardiac during Q1FY27
  - Glizid brand family grew 29% YoY in Q1FY27
- Healthy growth in BSVs key brands - Foligraf (39%), Humog (39%) and Anti-D (23%)
- Consistently maintained #1 rank over last 9 years with prescription share of 15.2%[1]

1.As per IQVIA Jun-2026 // 2.Denotes reported number// 3. Ex-Trizepatide

Consumer Healthcare Business[1]

- Revenue growth[2] of 4% YoY in Q1FY27 partly impacted by base effect of discontinued cash and carry business
- Despite softer growth, we gained market share[1] in key Brands – Manforce, Preganews and Gas-o-fast
- MT & E-Com share increased to 15% in Q1FY27 as compared to 11% in Q1FY26 supported by 38% growth
- Healthy growth in secondary sales for Gas-o-fast and Ova news of 10% and 36% YoY respectively in Q1FY27

1. As per IQVIA / IQVIA Retail, Jun-2026 // 2. Denotes reported number

Exports

- Revenue from International business[1] registered healthy growth of 29% YoY in Q1FY27
- Mankind (excluding BSV) has launched 1 new products in Q1FY27 taking the total launched products to 49 in US

1. Denotes reported number

Consolidated Profit & Loss Account

INR Crore	Q1 FY27	Q1 FY26	YoY%	Q4 FY26	QoQ%
Revenue from Operations	4,031	3,570	12.9%	3,443	17.1%
Gross Margins %	*72.8%*	*70.5%*	*230 bps*	*72.2%*	*60 bps*
EBITDA	1,060	850	24.7%	910	16.5%
EBITDA Margin %	*26.3%*	*23.8%*	*250 bps*	*26.4%*	*-10 bps*
Adj. EBITDA	1,060	850	24.7%	933[1]	13.6%
Adj. EBITDA Margin %	*26.3%*	*23.8%*	*250 bps*	*27.1%[1]*	*-80 bps*
PAT	574	445	29.1%	559	2.6%
PAT Margin %	*14.2%*	*12.5%*	*170 bps*	*16.2%*	*-200 bps*

1. Adjusted with one time impact of labour code regulations

Segmental Revenue Break Up

INR Crore	Q1 FY27	Q1 FY26	YoY%	Q4 FY26	QoQ%
Domestic	3,426	3,101	10.5%	2,886	18.7%
• *Domestic (Ex-CH)*	*3,180*	*2,864*	*11.0%*	*2,673*	*19.0%*
• *Consumer Healthcare*	*246*	*237*	*3.9%*	*213*	*15.5%*
Exports	605	469	29.0%	557	8.5%
Total	**4,031**	**3,570**	**12.9%**	**3,443**	**17.1%**

Earning concall Details

Date	**30th July, 2026**
Time	**06:30 pm – 07:30 pm IST**
Zoom Link	Click here

About Mankind Pharma

Mankind Pharma (BSE: 543904 | NSE: MANKIND) is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence. Mankind operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company is a leading player in the domestic pharmaceuticals business present across acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, gynaecology, VMN and respiratory, among others with a strategy to increase chronic presence going ahead. In the consumer healthcare business, the company operates in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories, among others, with several category-leading brands. Following the acquisition of BSV, Mankind Pharma has further strengthened its leadership in the domestic women's health segment. Mankind's distribution network includes a robust field force of 18,500+ professionals, and a reach extending to over five lakh doctors across urban and rural markets. The company has 32 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. Mankind has a consistent track record of product innovation through 7 dedicated R&D facilities backed by more than 740 scientists.

For more information, visit www.mankindpharma.com

Safe Harbour Statement

The statements, are as on date and may contain forward-looking statements like the words "believe", "expects", "anticipate", "aim", "will likely result", "Would", "will continue", "contemplate" "intends", "plans", "estimates", "seek to", "future", "objective", "projects", "goal", "likely", "Project", "should", "potential" "will", "may", "targeting" or other words of similar expressions/ meaning regarding the financial position, business strategy, plans, targets and objectives of the Company. Such forward-looking statements involve known and unknown risks which may cause actual results, performance or achievements to be materially different from the results or achievements expressed or implied. The risks and uncertainties inter-alia, relating to these statements include (i) cash flow projections, (ii) industry and market conditions; (iii) ability to manage growth; (iv) competition; (v) government policies and regulations; (vi) obtaining regulatory approvals; (vii) domestic & international economic conditions such as interest rate & currency exchange fluctuations; (viii) political, economic, legal and social conditions in India/ elsewhere; (ix) technological advances; (x) claims and concerns about product safety and efficacy; (xi) domestic and foreign healthcare reforms; (xii) inability to build production capacity; (xiii) unavailability of raw materials and failure to gain market acceptance.

The Company and its subsidiaries shall not have any responsibility or liability whatsoever for any loss howsoever arising from this presentation or its contents or otherwise arising in connection therewith. Also, Company assume no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent developments, information or events, or otherwise.

For Queries Contact

Mankind Pharma - Investor Relations
Prakash Agarwal
Email address: investor.relations@mankindpharma.com
Contact Number: +91-11-46846700

Mankind Pharma - Corporate Communication
Natasha Raj
Email address: natasha.raj@mankindpharma.com
Contact Number: 011-46846700 Ext: 3201

Adfactors PR - Investor Relations / Public Relations
Smit Shah / Apoorva Sharma
Email address: smit.shah@adfactorspr.com / apoorva.sharma@adfactorspr.com
Contact Number: +91 9870789596 / +91 9999739452